The global market for warm autoimmune hemolytic anemia (WAIHA) treatment achieved a valuation of USD 582.99 million in 2022 and is projected to experience substantial growth, reaching an estimated USD 1,598 million by 2033. This growth trajectory represents a notable compound annual growth rate (CAGR) of 9.6% over the forecast period from 2023 to 2033, …